Fig. 3: daLUXendin660 accesses circumventricular organs from the periphery.
From: Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain
a–c, Intravenous administration of 100 nmol kg−1 daLUXendin660 (n = 3 mice) (a), 100 nmol kg−1 daLUXendin660+ (n = 2 mice) (b) and subcutaneous administration of 100 nmol kg−1 LUXendin645 (GLP1R antagonist) (n = 5 mice) (c) led to staining in circumventricular organs of the brain and the choroid plexus. Shown are the organum vasculosum of the lamina terminalis (i), subfornical organ (ii), choroid plexus (iii), median eminence (iv) and area postrema (v). d,e, Intravenous administration of 100 nmol kg−1 daLUXendin660 in a GLP1R-tdRFP mouse (n = 1) (d) or GIPR-GCaMP6 mouse (n = 2) (e) labels GLP1R-expressing and GIPR-expressing cells, respectively (indicated by white arrows). Shown are the subfornical organ (i), median eminence (ii), area postrema (iii) and zoom-in of area postrema with merged (iii’), GLP1R-tdRFP/GIPR-GCaMP6 (iii’’) and daLUXendin660 (iii’’’) signals. Note that images in e are from the same mouse as in a but with GIPR-GCaMP6 signal overlaid. Scale bars, 100 µm.
